



**BIR/UCLH MASTERCLASS:
PROSTATE CANCER THERAGNOSTICS**
Venue: Leonardo Royal Hotel Tower Bridge, London



Bayer have part
funded this event

PHILIPS



**SIEMENS
Healthineers**



A Novartis Company

BIR/UCLH MASTERCLASS: PROSTATE CANCER THERAGNOSTICS

Venue: Leonardo Royal Hotel Tower Bridge, London
6 CPD CREDITS

Radiolabelled prostate-specific membrane antigen (PSMA) is increasingly used in imaging prostate cancer. PSMA theragnostics is emerging as a useful therapy in the treatment of mCRPC. This one-day masterclass will cover the spectrum of tracers and techniques related to PSMA theragnostics with lectures, panel discussions and relevant information for clinical practice. The masterclass will comprise of four sessions by clinical colleagues from the UK, Germany, Netherlands and USA.

Educational Aims:

- To review current role of radionuclide PSMA imaging in prostate cancer: tracers, indications, variants and pitfalls
- To explain how to report PSMA PET-CT scans
- To review current evidence and clinical trials
- To review current role of radionuclide PSMA therapy in prostate cancer: patient selection, administration, side effects and complications
- To understand how to set up a theragnostic unit

08:45 Registration and refreshments

09:15 Welcome and introduction

Dr Gopinath Gnanasegaran, Consultant Physician in Nuclear Medicine, Royal Free NHS Foundation Trust

Session I

Chair: Dr Jamshed Bomanji, Clinical Lead and Head of Clinical Department, Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust

09:20 Introduction to management of prostate cancer options

Dr Mark Prentice, Consultant Clinical Oncologist, Royal Free NHS Foundation Trust

09:40 PSMA PET tracers in prostate imaging: Biodistribution, variants and pitfalls

Dr Matthias Eiber, Associate Professor, The Technical University of Munich, Germany

10:10 PSMA imaging in prostate cancer: current evidence and ongoing trials

Dr Daniela Elena Oprea-Lager, Nuclear Medicine Physician, Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands

10:40 PSMA PET – Where are we now: Summary of a decade of PSMA PET: What PSMA can and can't do

Dr Asim Afaq, Clinical Associate Professor, Department of Radiology, Carver College of Medicine, University of Iowa Hospitals and Clinics and Honorary Consultant Radiologist, Institute of Nuclear Medicine, UCL/UCLH

Session II

Chair: Dr Daniela Elena Oprea-Lager, Nuclear Medicine Physician, Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands

11:00 Refreshments

11:30 Reporting PSMA scans – current trends

Dr Matthias Eiber, Associate Professor, The Technical University of Munich, Germany

12:00 What clinicians look for in a report and the impact of interpretation

Dr Asim Afaq, Clinical Associate Professor, Department of Radiology, Carver College of Medicine, University of Iowa Hospitals and Clinics and Honorary Consultant Radiologist, Institute of Nuclear Medicine, UCL/UCLH

12:20	Alternatives to PSMA PET including Tc99m PSMA, 18F-Fluciclovine, 18F-Choline Dr Stephan Voo, Consultant, University College London Hospital
12:40	PSMA imaging: Questions you wanted to ask Dr Gopinath Gnanasegaran, Consultant Physician in Nuclear Medicine, Royal Free NHS Foundation Trust
13:00	Lunch

Session III

Chair: Dr Shaunak Navalkissor, Consultant nuclear medicine physician, Royal Free NHS Foundation

14:00	177 Lu-PSMA radionuclide therapy: Patient selection, technique, management of side effects, and follow up Dr Yong Du, Consultant in Nuclear Medicine, The Royal Marsden Hospital
14:20	225Ac-PSMA radionuclide therapy: Patient selection, technique, management of side effects, and follow up Dr Mariza Vorster, Nuclear Medicine Physician, PhD Head of Department & Associate Professor: Nuclear Medicine, UKZN/IALCH, President of the College of Nuclear Physicians at Colleges of Medicine of South Africa
14:40	PSMA radionuclide therapy: Current evidence and clinical trials Dr Gopinath Gnanasegaran, Consultant Physician in Nuclear Medicine, Royal Free NHS Foundation Trust
15:00	Refreshments

Session IV

Chair: Dr Sabina Dizdarevic, Principal Lead Consultant in Imaging and Nuclear Medicine, Brighton and Sussex University Hospital Trust

15:30	What's next with PSMA – directions for research and outlook in the near to medium term Dr Simon Wan, Consultant Radiologist, University College London Hospitals NHS Foundation Trust
15:50	Panel discussion: Setting up and running a PSMA imaging and therapy service <i>Moderator: Dr Gopinath Gnanasegaran</i> <i>Panellists: Prof Jamshed Bomanji, Dr Shaunak Navalkissoor, Dr Yong Du, Dr Sabina Dizdarevic</i>
16:50	Radiation protection Dr Richard Meades, Radionuclide Therapy Lead Physicist, The Royal Free London NHS Foundation Trust
17:10	Dosimetry Dr John Dickson, Head of Clinical Nuclear Medicine Physics, University College London Hospitals NHS Foundation Trust
17:25	Closing of event

Upcoming events

BIR ANNUAL CONGRESS 2022

22-23 September 2022

Royal College of Physicians, London

STATE-OF-THE-ART NUCLEAR MEDICINE AND PIPELINE INDUSTRY DEVELOPMENTS

February 2023

Virtual event

Programme Organisers

Professor Jamshed Bomanji, Clinical Lead and Head of Clinical Department, Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust

Dr Gopinath Gnanasegaran, Consultant Physician in Nuclear Medicine, Royal Free NHS Foundation Trust

Join us

Join the BIR today to benefit from reduced delegate rates for our events.

For membership information visit:
www.bir.org.uk/join-us

BIR/UCLH MASTERCLASS:
PROSTATE CANCER THERAGNOSTICS
Leonardo Royal Hotel Tower Bridge, London



 @BIR_News

 /britishinstituteofradiology

 The British Institute of Radiology

48–50 St John Street, London, EC1M 4DG
www.bir.org.uk

Registered charity number: 215869

